Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II multi-center, randomized, double-blinded, controlled trial of CardiALLO-cell-therapy in ischemic systolic heat failure

Next Previous
Search
Trial Profile

Phase I/II multi-center, randomized, double-blinded, controlled trial of CardiALLO-cell-therapy in ischemic systolic heat failure

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CardiALLO cell therapy (Primary)
  • Indications Ischaemic heart disorders
  • Focus First in man; Therapeutic Use
  • Acronyms Allogeneic NK1R+ MSC Trial in HFrEF
  • Sponsors BioCardia

    • Most Recent Events

    • 13 Nov 2024 According to a BioCardia media release, The last patient in the low-dose cohort is expected to be enrolled in the fourth quarter of 2024 and DSMB safety readout for the low-dose cohort expected in Q1 2025.
    • 27 Mar 2024 According to a BioCardia media release, Completion of low-dose cohort expected in Q2 2024 and completion of medium-dose cohort is expected in Q4 2024.
    • 27 Mar 2024 Results from this trial presented at the Technology and Heart Failure Therapeutics meeting on March 4, 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top